FDA snubs Zogenix's anti-seizure drug, not happy with some sloppy, inadequate R&D work

Nine months after Zogenix got a stock rally $ZGNX going by touting late-stage data for a new drug to prevent seizures due to Dravet syndrome, the FDA handed back their marketing application with a failing grade on inadequate and incomplete work. Officially, that’s called a refuse-to-file notice, which is always embarrassing.